NCT05675319 2026-01-05
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
Clinical Trials
9 trialsNCT03590652 2025-10-21
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
Phase 2 Terminated
NCT04405167 2025-10-07
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
University of Pennsylvania
Phase 1 Terminated
NCT03457142 2025-03-04
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Roswell Park Cancer Institute
Phase 2 Terminated
NCT03683277 2025-02-19
IFM2014-01
Intergroupe Francophone du Myelome
Phase 2 Terminated
NCT03733691 2023-10-25
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
Oncotherapeutics
Phase 2 Terminated
NCT04119336 2023-08-21
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
Massachusetts General Hospital
Phase 2 Terminated
NCT02897830 2020-11-12
IFM2014-03
University Hospital, Toulouse
Phase 2 Terminated
NCT03492138 2020-05-29
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Phase 1/2 Terminated